leading glp-1 treatments for diabetes 2025 What is the pipeline future medications for obesity? GLP-1s in 2025: Who's Using

3 These findings move GLP-1s out of the weight-loss drug category and into the category of proven cardiovascular risk-reduction tools

Advances in Nutrition , 12 (6), 2540-2552

Currently, it is only FDA-approved for the treatment of type 2 diabetes, but is being studied for the treatment of obesity, as it was seen to cause significant weight loss

Probiotics : Early research suggests that probioticslive microorganisms in your digestive systemmay promote cells in the intestines to secrete GLP-1, thus improving insulin function

Your healthcare provider will tailor the dosage and frequency of semaglutide GLP-1 based on your individual needs, health profile, and progress